Ahrens Investment Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ahrens Investment Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$4.58K	Buy	+42	New	+$4.64K	﹤0.01%	774
2022 Q3	–	Sell	-42	Closed	-$3K	–	1012
2022 Q2	$3K	Hold	42	–	–	﹤0.01%	854
2022 Q1	$4K	Hold	42	–	–	﹤0.01%	895
2021 Q4	$5K	Buy	+42	New	+$4.58K	﹤0.01%	894

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ahrens Investment Partners's HZNP Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023: 42 shares worth $4.58K. The stake represents ﹤0.01% of the portfolio and ranks #774 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in HZNP as recently as Q2 2022.

Ahrens Investment Partners first reported a position in HZNP in Q4 2021 and has held it in 4 quarters since. The position peaked at $5K in Q4 2021. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Ahrens Investment Partners held 42 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $4.58K as of Q1 2023.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new Ahrens Investment Partners position in Q1 2023.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #774 holding.
Ahrens Investment Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and has held it in 4 quarters since.
Ahrens Investment Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5K in Q4 2021.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.